Evaluation of the Safety and Pharmacokinetics of Single-Dose Oral Probenecid Administration in Healthy Dogs
Journal of Veterinary Internal Medicine · 01.09.2025 · 39 (5)
DOI: 10.1111/jvim.70221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 01.09.2025. Verfasst von Margaret Cook und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA. Hauptthemen laut MEDLINE: Probenecid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Cancer Center, University of Colorado, College Research Council, Colorado State University College of Veterinary Medicine and Biomedical Sciences.
Abstract (Originalsprache)
Background
Grape-induced acute kidney injury (AKI) is caused by tartaric acid and may lead to death in dogs. Probenecid, an organic anion transporter-1 inhibitor, recently has been shown to block the uptake of tartaric acid in Madin–Darby canine kidney cells and has been suggested as a possible target for prevention of AKI after grape ingestion. Hypothesis/Aims Assess the safety and pharmacokinetics (PK) of PO probenecid in dogs. We hypothesized that probenecid would result in mild, self-limiting gastrointestinal (GI) adverse effects and would be safe in healthy dogs. Additionally, we hypothesized that PO probenecid (50 mg/kg) would have adequate bioavailability and achieve pharmacologically active plasma drug concentrations. Animals Six healthy beagle dogs.
Methods
Pharmacokinetic (PK) study. Dogs were given 50 mg/kg of probenecid PO, with PK data collected for 48 h after administration. Complete blood count, serum biochemistry profile, urinalysis, and clinical monitoring were performed throughout a 21-day study period to assess safety. Plasma concentration versus time data was analyzed using non-compartmental and two-compartmental modeling.
Results
Orally administered probenecid had excellent estimated bioavailability (82.6%) and rapid absorption, with a mean maximal plasma concentration of 589.3 μM (range: 368.0–830.5 μM) within 1.5 h. The mean volume of distribution was 0.71 L/kg, with mean systemic clearance of 0.022 L/h/kg and mean half-life of 24.1 h. Probenecid was well tolerated by all six dogs, with no clinically relevant adverse effects noted. Conclusions and Clinical Importance Orally administered probenecid is safe and bioavailable in healthy dogs. Future clinical trials assessing PO probenecid in dogs with known tartaric acid ingestion are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA.
ORCID-Profile: Margaret Cook
Förderung
- NCI NIH HHS
- Cancer Center, University of Colorado
- College Research Council, Colorado State University College of Veterinary Medicine and Biomedical Sciences
Zitieren
APA
Cook, M., Gustafson, D. L., Kroeker, K., Shropshire, S., & Zersen, K. M. (2025). Evaluation of the Safety and Pharmacokinetics of Single-Dose Oral Probenecid Administration in Healthy Dogs. Journal of Veterinary Internal Medicine, 39(5). https://doi.org/10.1111/jvim.70221
Vancouver
Cook M, Gustafson DL, Kroeker K, Shropshire S, Zersen KM. Evaluation of the Safety and Pharmacokinetics of Single-Dose Oral Probenecid Administration in Healthy Dogs. Journal of Veterinary Internal Medicine. 2025;39(5). doi:10.1111/jvim.70221
BibTeX
@article{Cook2025,
author = {Cook, Margaret and Gustafson, Daniel L and Kroeker, Katie and Shropshire, Sarah and Zersen, Kristin M},
title = {Evaluation of the Safety and Pharmacokinetics of Single-Dose Oral Probenecid Administration in Healthy Dogs},
journal = {Journal of Veterinary Internal Medicine},
year = {2025},
volume = {39},
number = {5},
doi = {10.1111/jvim.70221}
}
EUVIMED